This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
The company also reported significant progress toward its internally defined Sustainable Development Goals
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
The initiative is focused on a problem that continues to plague cancer outcomes in India
The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
The center will deliver Certified Pre-Owned instruments restored to factory-grade standards and backed by Agilent Standard Warranty
Subscribe To Our Newsletter & Stay Updated
